Skip to content

Study · Randomized controlled trial · n = 832 · 2007

3 results

Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.

Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, Li PM, Fan ZN, Sun WS, Shen YZ, Ma SR, Xie WF, Chen MH, Li YQ

The American journal of gastroenterology1 Jan 2007Cited by 51 (Europe PMC)

PMID17266687 (opens in a new tab)DOI10.1111/j.1572-0241.2006.00959.x (opens in a new tab)PepBankPUB-17266687
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ERCP patients, pancreatitis occurred in 10/414 (2.42%) with octreotide versus 22/418 (5.26%) with placebo (P=0.046).

    In plain wordsIn ERCP patients, octreotide reduced pancreatitis compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePost-ERCP pancreatitis
    Study

    n = 832

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusion · intravenous and subcutaneous · Intravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedAs given in this study (human).

    Measurements

    Incidence of acute pancreatitis
    2.42%
    octreotide group, 10/414
    Incidence of acute pancreatitis
    5.26%
    control group, 22/418
    Overall incidence of acute pancreatitis
    3.85%
    both groups
    P value
    0.046 P
    octreotide vs control

    Source sentences

    Summary
    The overall incidence of acute pancreatitis was 3.85%; this included 2.42% (10/414) in the octreotide group and 5.26% (22/418) in the control group (P = 0.046).
    4 context sentences
    Summary · context
    Patients were randomized into two groups: an octreotide group (N = 414) and a control group (N = 418).
    Summary · context
    In the octreotide group, octreotide (0.3 mg) was dissolved in 500 mL of 0.9% saline solution and administered by continuous intravenous infusion, beginning 1 h before endoscopic examination and continued for 6 h thereafter;
    Summary · context
    0.1 mg of octreotide was injected subcutaneously at 6 and 12 h after the intravenous injection was stopped.
    Summary · context
    The control group was given a placebo intravenously.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In ERCP patients, hyperamylasemia occurred in 51/414 (12.32%) with octreotide versus 73/418 (17.46%) with placebo (P=0.041).

    In plain wordsIn ERCP patients, octreotide reduced high amylase levels compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseHyperamylasemia
    Study

    n = 832

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusion · intravenous and subcutaneous · Intravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedAs given in this study (human).

    Measurements

    Incidence of hyperamylasemia
    12.32%
    octreotide group, 51/414
    Incidence of hyperamylasemia
    17.46%
    control group, 73/418
    Overall incidence of hyperamylasemia
    14.9%
    both groups
    P value
    0.041 P
    octreotide vs control

    Source sentences

    Summary
    The overall incidence of hyperamylasemia was 14.9%; 12.32% (51/414) in the octreotide group and 17.46% (73/418) in the control group (P = 0.041).
    4 context sentences
    Summary · context
    Patients were randomized into two groups: an octreotide group (N = 414) and a control group (N = 418).
    Summary · context
    In the octreotide group, octreotide (0.3 mg) was dissolved in 500 mL of 0.9% saline solution and administered by continuous intravenous infusion, beginning 1 h before endoscopic examination and continued for 6 h thereafter;
    Summary · context
    0.1 mg of octreotide was injected subcutaneously at 6 and 12 h after the intravenous injection was stopped.
    Summary · context
    The control group was given a placebo intravenously.
  3. 03HumanNon-randomized trialSafety outcome

    In the ERCP trial of prophylactic octreotide versus placebo, no side effects were found.

    In plain wordsIn the ERCP trial of octreotide versus placebo, no side effects were found.

    Peptide
    Octreotide
    Outcome
    Not applicableSide effects
    Study

    n = 832

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusion · intravenous and subcutaneous · Intravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedAs given in this study (human).

    Source sentences

    Summary
    No side effects were found.
    4 context sentences
    Summary · context
    Patients were randomized into two groups: an octreotide group (N = 414) and a control group (N = 418).
    Summary · context
    In the octreotide group, octreotide (0.3 mg) was dissolved in 500 mL of 0.9% saline solution and administered by continuous intravenous infusion, beginning 1 h before endoscopic examination and continued for 6 h thereafter;
    Summary · context
    0.1 mg of octreotide was injected subcutaneously at 6 and 12 h after the intravenous injection was stopped.
    Summary · context
    The control group was given a placebo intravenously.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.